Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 17, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2024
September 16, 2024 12:44 ET
|
Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi: Information concerning the total number of voting rights and shares - August 2024
September 16, 2024 12:44 ET
|
Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
Saudi Arabia $13.99 Bn Pharmaceutical Market Trends, Competition, Forecast & Opportunities, 2029F
September 16, 2024 10:46 ET
|
Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Saudi Arabia Pharmaceutical Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
The American Urological Association Expands Partnership with Verana Health for the AQUA Registry
September 12, 2024 10:05 ET
|
American Urological Association
BALTIMORE, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA), the world’s leading urology association, has announced a partnership expansion with Verana Health, a digital...
India Pharmaceutical Industry Research 2024: $105+ Billion Market Trends, Regional Insights, Competition, Forecasts and Opportunities, 2020-2030
September 11, 2024 11:50 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Pharmaceutical Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024 01:04 ET
|
Regeneron Pharmaceuticals, Inc.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is...
ViaDerma Completes First Shipment of 500,000 Units to Nigeria
September 10, 2024 08:00 ET
|
ViaDerma, Inc.
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to...
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference